Prenatal Exposure to Serotonin Reuptake Inhibitors and Congenital Heart Anomalies: An Exploratory Pharmacogenetics Study

Daud, Aizati N. A.; Bergman, Jorieke E. H.; Kerstjens-Frederikse, Wilhelmina S.; Vlies, Pieter van der; Berger, Rolf M. F.; Groen, Henk; Wilffert, Bob

doi:10.2217/pgs-2017-0036

Cited by 5 publications

(2 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This could bias our results toward the null hypothesis. Importantly, other factors that potentially contribute to an increased risk of SSRI-associated congenital heart defects were not considered, including genetic polymorphisms, and genetic variants in folate, homocysteine, or transsulfuration pathways [34, 35]. We were unable to evaluate if a dose-dependent effect was present or further parse out the effects of the particular SSRI due to our limited sample size, and lack of variability in agent used, as most mothers were taking sertraline.…”

Section: Discussionmentioning

confidence: 99%

A Prospective Study Evaluating the Effects of SSRI Exposure on Cardiac Size and Function in Newborns

et al. 2019

View full text Add to dashboard Cite

Background: Selective serotonin reuptake inhibitors (SSRIs) are antidepressants prescribed in 10% of pregnancies in the USA. We have previously shown in preclinical studies that sertraline exposure impacts cardiomyocyte development, leading to reductions in left ventricular size and cardiac function. Objectives: We hypothesized that in utero SSRI exposure will lead to reduced left ventricular dimensions and cardiac function on echocardiography immediately after birth. Methods: Twenty term infants with and 21 term infants without in utero exposure to SSRIs underwent echocardiograms to assess cardiac size and function. The exclusion criteria for infants were prematurity, small or large for gestational age, any respiratory or cardiovascular support needed after birth, and any major congenital malformation. Results: Infants exposed to in utero SSRIs had significantly reduced right ventricular dimensions in the diastole (controls 1.0 cm [0.86, 1.20], SSRI 0.89 cm [0.730, 1.05], p = 0.03), and left ventricular lengths in the diastole and systole (diastole: controls 3.4 cm [3.25, 3.65], SSRI 3.25 cm [3.10, 3.45], p = 0.03; systole: controls 2.9 cm [2.65, 3.05], SSRI 2.6 cm [2.50, 2.85], p = 0.01). No differences were observed in cardiac function. Importantly, there were no differences in maternal conditions or infant birth weight, body surface area, or gestational age. Conclusions: Our findings suggest an association between in utero exposure to SSRIs and ventricular size in infants. Given the increasing use of SSRIs during pregnancy and the importance of early life programming on future cardiovascular health, larger studies need to be completed to determine if in utero SSRI exposure impacts ventricular size.

show abstract

Section: Discussionmentioning

confidence: 99%

A Prospective Study Evaluating the Effects of SSRI Exposure on Cardiac Size and Function in Newborns

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The most recent articles chosen to be free to access by our Editor in Chief Professor David Gurwitz and are below: r Yusuf N et al An epigenome-wide association study of inflammatory response to fenofibrate in the Genetics of Lipid Lowering Drugs and Diet Network [4]; r Borse MS et al CYP2C19-guided antiplatelet therapy: a cost-effectiveness analysis of 30 day and 1 year outcomes following percutaneous coronary intervention [5]; r Liu et al Influence of common and rare genetic variation on warfarin dose among African-Americans and European-Americans using the exome array [6]; r Daud ANA et al Prenatal exposure to serotonin reuptake inhibitors and congenital heart anomalies: an exploratory pharmacogenetics study [7].…”

Section: Looking Forward: 2018mentioning

confidence: 99%

Welcome to the 19th Volume of Pharmacogenomics

Jones

2017

Pharmacogenomics

View full text Add to dashboard Cite

Fluoxetine/paroxetine/venlafaxine

2018

Reactions Weekly

View full text Add to dashboard Cite

Prenatal Exposure to Serotonin Reuptake Inhibitors and Congenital Heart Anomalies: An Exploratory Pharmacogenetics Study

Abstract: We identified several polymorphisms that might potentially affect the risk of CHA among exposed fetuses, which warrants further investigation.

Cited by 5 publications

References 58 publications

A Prospective Study Evaluating the Effects of SSRI Exposure on Cardiac Size and Function in Newborns

A Prospective Study Evaluating the Effects of SSRI Exposure on Cardiac Size and Function in Newborns

Welcome to the 19th Volume of Pharmacogenomics

Fluoxetine/paroxetine/venlafaxine

Contact Info

Product

Resources

About